Amgen, Inc. (NASDAQ:AMGN) announced voting results from the Company’s Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 88 percent of outstanding shares were represented at the meeting. Amgen, Inc. (NASDAQ:AMGN) net profit margin is 24.90% and weekly performance is 0.97%. On last trading day company shares ended up $111.94. Analysts mean target price for the company is $132.78. Amgen, Inc. (NASDAQ:AMGN) distance from 50-day simple moving average (SMA50) is -4.69%.
Pfizer Inc. (NYSE:PFE) upped the ante in its pursuit of AstraZeneca yesterday, increasing its offer to £55.00 per share from £50 and insisting it was not prepared to go any higher. AZ swiftly moved to reject the offer, however, saying it “falls short of AZ’s value as an independent science-led company.” Pfizer Inc. (NYSE:PFE) shares advanced 0.21% in last trading session and ended the day on $29.12. Gross Margin is 81.90% and its return on assets is 23.00%. Pfizer Inc. (NYSE:PFE) quarterly performance is -8.02%.
Sanofi SA (ADR) (NYSE:SNY) got a nice little bump in its stock price following the 1-2 punch it landed at the end of last month. The company provided a crucial update on pivotal Phase III efficacy studies on its dengue vaccine. The following day, Sanofi released its first quarter reported which included an optimistic outlook for the full year EPS. Sanofi SA (ADR) (NYSE:SNY) shares moved up 0.93% in last trading session and was closed at $53.10, while trading in range of $52.68 -$53.10. Sanofi SA (ADR) (NYSE:SNY) year to date (YTD) performance is 2.61%.
Japanese firms ASKA Pharmaceutical and Takeda Pharmaceutical Co Ltd (ADR) have entered into a distribution agreement for Candesartan ‘ASKA’ (candesartan cilexetil), a drug indicated for the treatment of hypertension. Candesartan ASKA is an authorized generic (AG) of Blopress (candesartan cilexetil), which Takeda has licensed the patent to Aska. Aska had received approval for the drug from the Japanese Ministry of Health, Labour and Welfare in February 2014, and is currently applying for listing on the National Health Insurance (NHI) Price List for June 2014. Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) ended the last trading day at $22.30.
ASTELLAS PHARMA INC (OTCMKTS:ALPMY) reported that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain. Previously announced topline data showed that the randomized, double-blind SECURE study met the primary objective of demonstrating non-inferiority of isavuconazole versus voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus species or certain other filamentous fungi. ASTELLAS PHARMA INC (OTCMKTS:ALPMY) On last trading day company shares ended up $11.74.
Leave a Reply